Dual SGLT1/SGLT2 inhibitors, such as canagliflozin [37] and LX4211 [38], have been introduced in the diabetes pharmacopeia; however, bronchial inflammation, airway damage and reduction of survival rate should be considered in patients with sepsis. Here, SLC5A2 is linked to diabetes mellitus.